{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:41Z","timestamp":1793157941699,"version":"4.5.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0115161","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T08:10:10Z","timestamp":1418976610000},"page":"e115161","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01450280","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eoghan","family":"de Barra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne H.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly M.","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie","family":"Hennigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Berrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"ref1","unstructured":"WHO (2012) World Malaria report 2012. Available: http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2012\/en\/index.html<\/ext-link>. WHO. ISBN 978 92 4 156453 3 ISBN 978 92 4 156453 3. Annual global report p."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/222488a0","article-title":"Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites","volume":"222","author":"RS Nussenzweig","year":"1969","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00000441-197309000-00002","article-title":"Immunization of man against sporozite-induced falciparum malaria","volume":"266","author":"DF Clyde","year":"1973","journal-title":"Am J Med Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0035-9203(74)90129-1","article-title":"Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum","volume":"68","author":"KH Rieckmann","year":"1974","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/339409","article-title":"Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites","volume":"185","author":"SL Hoffman","year":"2002","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2409595","article-title":"Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria","volume":"228","author":"F Zavala","year":"1985","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nm0498-397","article-title":"Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara","volume":"4","author":"J Schneider","year":"1998","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/519743","article-title":"Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells","volume":"196","author":"O Jobe","year":"2007","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.4049\/jimmunol.0900302","article-title":"Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes","volume":"183","author":"A Trimnell","year":"2009","journal-title":"J Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.4049\/jimmunol.171.4.2024","article-title":"Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells","volume":"171","author":"D Berenzon","year":"2003","journal-title":"J Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2353\/ajpath.2007.060792","article-title":"Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells","volume":"171","author":"AK Mueller","year":"2007","journal-title":"Am J Pathol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/519742","article-title":"Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells","volume":"196","author":"AS Tarun","year":"2007","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1073\/pnas.88.8.3300","article-title":"Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein","volume":"88","author":"A Malik","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/330664a0","article-title":"Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites","volume":"330","author":"L Schofield","year":"1987","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.4049\/jimmunol.165.3.1453","article-title":"The complexity of protective immunity against liver-stage malaria","volume":"165","author":"DL Doolan","year":"2000","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1016\/j.vaccine.2005.10.058","article-title":"Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers","volume":"24","author":"DP Webster","year":"2006","journal-title":"Vaccine"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"SJ McConkey","year":"2003","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1128\/IAI.00590-06","article-title":"A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge","volume":"74","author":"SJ Dunachie","year":"2006","journal-title":"Infect Immun"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"DP Webster","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"SH Sheehy","year":"2012","journal-title":"Mol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"GA O'Hara","year":"2012","journal-title":"J Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","article-title":"Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults","volume":"8","author":"C Ogwang","year":"2013","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1098\/rstb.2011.0091","article-title":"Vaccines against malaria","volume":"366","author":"AV Hill","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.vaccine.2010.10.041","article-title":"Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates","volume":"29","author":"S Capone","year":"2010","journal-title":"Vaccine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"CS Rollier","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/sj.mt.6300078","article-title":"A CD46-binding chimpanzee adenovirus vector as a vaccine carrier","volume":"15","author":"N Tatsis","year":"2007","journal-title":"Mol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy","volume":"27","author":"M Dudareva","year":"2009","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"KJ Ewer","year":"2013","journal-title":"Nat Commun"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"SH Sheehy","year":"2011","journal-title":"Mol Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.vaccine.2005.12.041","article-title":"A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S\/AS02A and MVA-CS","volume":"24","author":"SJ Dunachie","year":"2006","journal-title":"Vaccine"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1128\/IAI.74.5.2706-2716.2006","article-title":"Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein","volume":"74","author":"M Walther","year":"2006","journal-title":"Infect Immun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/501459","article-title":"Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya","volume":"42","author":"P Bejon","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1016\/j.vaccine.2004.03.050","article-title":"Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif","volume":"22","author":"O Bruna-Romero","year":"2004","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1084\/jem.20040989","article-title":"The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion","volume":"201","author":"A Coppi","year":"2005","journal-title":"J Exp Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cell.2007.09.013","article-title":"Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite","volume":"131","author":"AP Singh","year":"2007","journal-title":"Cell"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-1759(01)00535-X","article-title":"A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays","volume":"260","author":"JR Currier","year":"2002","journal-title":"J Immunol Methods"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.vaccine.2010.12.104","article-title":"A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects","volume":"29","author":"MC Keefer","year":"2011","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"P Bejon","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1086\/421118","article-title":"Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men","volume":"189","author":"VS Moorthy","year":"2004","journal-title":"J Infect Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pmed.0010033","article-title":"A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults","volume":"1","author":"VS Moorthy","year":"2004","journal-title":"PLoS Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","article-title":"Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component","volume":"6","author":"C Tamminga","year":"2011","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults","volume":"6","author":"M Sedegah","year":"2011","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1074-7613(00)80513-0","article-title":"Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles","volume":"7","author":"DL Doolan","year":"1997","journal-title":"Immunity"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"SH Sheehy","year":"2012","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1016\/j.vaccine.2006.06.022","article-title":"Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men","volume":"24","author":"EB Imoukhuede","year":"2006","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2875-11-11","article-title":"A review of malaria vaccine clinical projects based on the WHO rainbow table","volume":"11","author":"L Schwartz","year":"2012","journal-title":"Malar J"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1473-3099(10)70262-0","article-title":"Efficacy of RTS,S\/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5\u201317 months in Kenya and Tanzania: a randomised controlled trial","volume":"11","author":"A Olotu","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e61395","DOI":"10.1371\/journal.pone.0061395","article-title":"The Relationship between RTS,S Vaccine-Induced Antibodies, CD4(+) T Cell Responses and Protection against Plasmodium falciparum Infection","volume":"8","author":"MT White","year":"2013","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"KE Kester","year":"2009","journal-title":"J Infect Dis"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e25786","DOI":"10.1371\/journal.pone.0025786","article-title":"Circumsporozoite-specific T cell responses in children vaccinated with RTS,S\/AS01E and protection against P falciparum clinical malaria","volume":"6","author":"A Olotu","year":"2011","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2008.02.048","article-title":"Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S\/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research","volume":"26","author":"KE Kester","year":"2008","journal-title":"Vaccine"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0115161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T15:47:39Z","timestamp":1566143259000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0115161"}},"subtitle":[],"editor":[{"given":"Thomas L.","family":"Richie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0115161","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}